Revelar Biotherapeutics and Twist Bioscience Announce RBT-0813 Neutralizes SARS-CoV-2 Omicron (B.1.1.529/BA.1) and Delta (B.1.617.2) Variants

BETHESDA, Md. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Revelar Biotherapeutics, Inc. and Twist Bioscience Corporation (Nasdaq: TWST) today announced that RBT-0813 binds to and neutralizes the Omicron and Delta variants of SARS-CoV-2 in live virus studies. RBT-0813 is an innovative bispecific antibody discovered by Twist Biopharma and licensed to Revelar Biotherapeutics...

Click to view original post